There are a growing number of examples where pharmacogenomic data have allowed a compound to progress in development which would otherwise have been terminated. (For a recent example, see Risner et al, 2006, Pharmacogenomics J, 6 246-254).

PGXIS is especially keen to apply its expertise to help progress compounds which have failed in clinical development. This is an area that could have significant impact on patient's treatment.

If you have a compound which has failed during development, please contact us so we can meet to discuss your compounds.